Skip to Content
Merck
All Photos(4)

Key Documents

View All Documentation

T7650

Sigma-Aldrich

3,3′,5-Triiodothyroacetic acid

≥90%

Synonym(s):

4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylacetic acid

Sign Into View Organizational & Contract Pricing
All Photos(4)

About This Item

Empirical Formula (Hill Notation):
C14H9I3O4
CAS Number:
51-24-1
Molecular Weight:
621.93
EC Number:
200-086-1
MDL number:
MFCD00055931
UNSPSC Code:
12352100
PubChem Substance ID:
57654700
NACRES:
NA.22

Quality Level

200

Assay

≥90%

form

powder

storage temp.

−20°C

SMILES string

OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1

InChI

1S/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)

InChI key

UOWZUVNAGUAEQC-UHFFFAOYSA-N

Gene Information

human ... THRA(7067) , THRB(7068)
rat ... Thra(81812) , Thrb(24831)

Application


  • Thyroid hormone research: A study explored the impact of 3,3′,5-Triiodothyroacetic acid on peripheral and neurodevelopmental findings in patients with MCT8 deficiency, highlighting its potential in therapeutic interventions for thyroid-related developmental disorders (Unsal and Hayran, 2024).

  • Neurological disorder management: Research demonstrated the use of 3,3′,5-Triiodothyroacetic acid in addressing impaired T3 uptake and action in cerebral organoids modeling Allan-Herndon-Dudley syndrome, providing insights into its application in managing brain-specific thyroid hormone transport abnormalities (Salas-Lucia et al., 2024).

  • Pharmaceutical development for antiviral therapies: Tiratricol, a derivative of 3,3′,5-Triiodothyroacetic acid, was identified as an inhibitor of yellow fever virus replication by targeting the viral RNA-dependent RNA polymerase, showcasing its potential in antiviral drug development (Ren et al., 2023).

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302 + H312 + H332

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000375595
0000375595
0000333274
0000285206
0000285205

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Debora Lucia Seguro Danilovic et al.
Thyroid : official journal of the American Thyroid Association, 18(6), 655-657 (2008-06-27)
Mesotherapy consists of cutaneous injections of a mixture of compounds and has recently been used for cosmetic purposes to reduce local fat and cellulite. To date, several reports have described only local adverse events related to this therapy. We describe
Leandro Martínez et al.
Journal of medicinal chemistry, 49(1), 23-26 (2006-01-06)
Steered molecular dynamics simulations of ligand dissociation from Thyroid hormone receptors indicate that dissociation is favored via rearrangements in a mobile part of the LBD comprising H3, the loop between H1 and H2, and nearby beta-sheets, contrary to current models
Rie Anzai et al.
Thyroid : official journal of the American Thyroid Association, 22(10), 1069-1075 (2012-09-06)
The effectiveness of short-term 3,5,3'-triiodothyroacetic acid (TRIAC) therapy for the treatment of hyperthyroidism caused by thyroid hormone resistance (RTH) has been documented. Here, we report a 3-year course of TRIAC therapy in an RTH boy, with a quantitative evaluation of
Napoleão F Valadares et al.
Bioorganic & medicinal chemistry, 15(13), 4609-4617 (2007-05-01)
2D QSAR studies were carried out for a series of 55 ligands for the Thyroid receptors, TRalpha and TRbeta. Significant cross-validated correlation coefficients (q(2)=0.781 (TRalpha) and 0.693 (TRbeta)) were obtained. The models' predictive abilities were proved more valuable than the
Christopher J Ryerson et al.
Journal of pain and symptom management, 43(4), 771-782 (2012-01-31)
Little is known about the treatment and correlates of dyspnea in idiopathic pulmonary fibrosis (IPF). The objective of this systematic review was to summarize the literature regarding the treatment and correlates of dyspnea in IPF. MEDLINE, EMBASE, and all Evidence-Based
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service